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Background: Hendra virus (HeV) is an Australian bat-borne zoonotic paramyxovirus that repeatedly spills-over to
horses causing fatal disease. Human cases have all been associated with close contact with infected horses.
Methods: A full-length antigenome clone of HeV was assembled, a reporter gene (GFP or luciferase) inserted
between the P and M genes and transfected to 293T cells to generate infectious reporter gene-encoding
recombinant viruses. These viruses were then assessed in vitro for expression of the reporter genes. The GFP
expressing recombinant HeV was used to challenge ferrets to assess the virulence and tissue distribution by
monitoring GFP expression in infected cells.
Results: Three recombinant HeV constructs were successfully cloned and rescued; a wild-type virus, a GFP-
expressing virus and a firefly luciferase-expressing virus. In vitro characterisation demonstrated expression of the
reporter genes, with levels proportional to the initial inoculum levels. Challenge of ferrets with the GFP virus
demonstrated maintenance of the fatal phenotype with disease progressing to death consistent with that observed
previously with the parental wild-type isolate of HeV. GFP expression could be observed in infected tissues
collected from animals at euthanasia.
Conclusions: Here, we report on the first successful rescue of recombinant HeV, including wild-type virus and
viruses expressing two different reporter genes encoded as an additional gene cassette inserted between the P and
M genes. We further demonstrate that the GFP virus retained the ability to cause fatal disease in a well-
characterized ferret model of henipavirus infection despite the genome being an extra 1290 nucleotides in length.
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Zoonotic diseaseBackground
Hendra virus (HeV) is a zoonotic paramyxovirus har-
boured by Australian mainland flying foxes from which it
is believed to be transmitted directly to horses. HeV first
emerged in 1994 in Hendra, a suburb of Brisbane,
Australia, leading to an outbreak of acute respiratory dis-
ease in 21 thoroughbred horses, of which 14 died [1-3].
During this outbreak, two horse trainers also became
infected with the virus, one fatally. In horses, HeV causes a
severe, often fatal, febrile illness associated with respira-
tory and neurological signs [4]. Since its emergence in* Correspondence: glenn.marsh@csiro.au
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reproduction in any medium, provided the orQueensland, Australia in 1994, HeV spillover from flying
foxes to horses has regularly recurred: with an increase in
disease events occurring over the past two years [5].
Thirty-nine disease events have occurred resulting in the
death or euthanasia of seventy-six horses and one dog,
with a case fatality of 75% in the horses.
HeV is the prototype species of the genus Henipavirus,
within the subfamily Paramyxovirinae [6,7]. Nipah virus
(NiV) is the only other virus officially classified within
the Henipavirus genus. NiV was first identified during a
major outbreak of acute respiratory disease in pigs in
peninsular Malaysia in 1998–99. Over one million pigs
were culled in Malaysia to prevent the continued spread
of the virus. Over 265 farm and abattoir workers ex-
posed to infected pigs were infected by NiV, resulting intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Schematic representation of the genomes of each of
the recombinant viruses. Full gene cassettes including the 5’UTR
from the M gene, the reporter gene and the 3’ UTR of the P gene
were inserted for expression of the GFP or luciferase.
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Since the outbreak of disease in Malaysia and Singapore,
NiV re-emerged in Bangladesh in 2001, with continued
re-emergence and human cases almost annually since
in Bangladesh and sporadically in India [11,12]. Differ-
ences in transmission have also been observed between
the Bangladesh and Malaysian strains of NiV. NiV
Bangladesh has been shown to cause direct bat-to-hu-
man transmission without the involvement of an inter-
mediary or amplifying host. Human-to-human spread of
NiV in Bangladesh has also been documented [12-15].
Because of the broad host range and the high mortality
rates associated with these viruses, both HeV and NiV
have been classified as a biosafety level 4 (BSL-4) agents.
Recently, we described a novel paramyxovirus, Cedar
virus (CedPV), which displayed many of the distinguishing
characteristics of the henipaviruses, including similar gen-
ome length and organisation, it displayed antigenic cross-
reactivity with henipaviruses and used the same host cell
molecule (ephrin B2) as a receptor for entry during infec-
tion [16]. Interestingly in preliminary animal challenge
studies, CedPV did not cause disease in ferrets and guinea
pigs, both of which are susceptible to fatal disease by the
henipaviruses. In addition, a near full length genome se-
quence has been described for a bat-borne virus from
Ghana, Africa [17], that shows around 50% sequence iden-
tity with the henipaviruses, including CedPV. Henipa-like
viruses have also been detected serologically in bats in
Thailand [18], China [19], Madagascar [20] and West
Africa [21], with successful virus isolation obtained from
Lyle’s flying foxes in Cambodia [22].
Reverse genetics of negative strand RNA viruses al-
low for the creation of recombinant infectious and
replication-competent viruses with specific mutations or
insertions. Often, researchers have inserted the green
fluorescent protein (GFP) gene into such viruses
allowing for the real-time monitoring of virus replication
and spread, either within cell culture or in vivo within
an infected host. The expression of GFP allows for the
detection of virus infection in tissues without the need
for antibody-specific detection methods. The generation
of recombinant henipaviruses will be an extremely
powerful tool to monitor viral infections both in real-
time for imaging and in a high-throughput approach for
screening activities. They will also play a pivotal role in
our understanding of pathogenesis of henipaviruses at
the molecular level through the generation, rescue and
testing of specific mutation variants. Rescue systems
have previously been reported for NiV [23-25], here we
report the generation of recombinant HeV in which the
GFP (HeV-GFP) or firefly luciferase gene (HeV-Luc) has
been inserted as an additional transcriptional unit be-
tween the P and M genes, and we assess their biological
characteristics both in vitro and in vivo.Results and discussion
Rescue of recombinant viruses
A full length antigenome clone of HeV (Hendra virus/
horse/1994/Hendra) was prepared and used for modifi-
cation by the insertion of GFP and firefly luciferase re-
porter genes. Reporter genes were inserted between the
P and M genes, including the untranslated regions from
the 3’ end of the P gene and the 5’ end of the M gene
(Figure 1). The rule of six was maintained in both the
GFP and luciferase constructs (HeV-GFP: 19,524 nucleo-
tides; HeV-Luc: 20,460 nucleotides). The HeV-GFP con-
struct is similar to a NiV-GFP infectious clone previously
reported [25], however in the NiV-GFP virus, GFP was
inserted between the N and P genes. In this study, the re-
porter genes were inserted between P and M in order to
keep the ratio of N and P consistent with wild-type virus.
This was considered important for optimal replication and
for maintenance of full virulence. The full HeV-Luc
construct at 20,460 nucleotides resulted in the largest
reported genome of a paramyxovirus.
Rescue of recombinant HeV for wild-type, HeV-GFP
and HeV-Luc viruses were achieved by co-transfection
of human 293T cell in 12.5 cm2 flasks with the full
length antigenome plasmid, N, P and L protein expres-
sion vector and pCAGGS T7 RNA polymerase. Two
days after transfection, Vero cells (5 × 105 cells) were
added to the 293T cell monolayers. In successful experi-
ments, CPE was obvious within 3 days following the
addition of the Vero cells, with CPE reaching maximal
levels around 7 days post transfection. Supernatants
were collected from the transfected cell monolayers and
clarified by centrifugation and used to infect Vero cell
monolayers to prepare virus stocks for further study.
In vitro characterisation
Growth characteristics of the 3 recombinant viruses
were compared in Vero cells (Figure 2). Replication of
each virus followed a similar pattern, at 24 hours, the re-
combinant viruses show slightly lower titres compared to
the parental virus however, and all reached a maximal titre
of 3–5 × 107 TCID50/mL by 48 hours post infection.
In order to determine expression of the GFP reporter
genes within infectious virus, cells were infected with
HeV-GFP an MOI of 0.01 and imaged by fluorescent
Figure 2 Kinetics of recombinant virus growth in Vero cells.
Vero cells were infected at an MOI of 0.01 and samples collected for
titration at 8, 24, 48 and 72 hours post infection. Results are
expressed as the average of 3 independent infections, with error
bars representing standard deviation.
Figure 3 Expression of GFP in Vero cells infected with HeV-GFP
recombinant virus. Vero cells were infected at an MOI of 0.05 and
imaged using a AMG EVOS FL fluorescent inverted microscope with
a monochrome camera at 24 and 48 hr post infection.
Figure 4 Expression of luciferase by the recombinant HeV-Luc.
Vero, HeLa, HEp2 and U373 human cells were infected with various
amounts of HeV-Luc. At 24 hours post infection, luciferase activity in
cells was measured by lysing cells using BrightGlo reagent
(Promega) and reading on a Synergy H4 microplate reader (Biotek
Instruments Inc). Results represent the average of 4 independent
infections with error bars representing standard deviation. All values
have been normalised to uninfected cells (relative light units of 1).
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tive cells were visible at 24 hours post infection and by
48 hours all cells were fluorescent, consistent with the
spread of virus and infection of all cells by 48 hours
(Figure 3). Stable GFP expression by HeV-GFP was
assessed by serially passing the virus 5 times to fresh
cell. Strong GFP expression was maintained through the
5 passes. The GFP expression allows for real-time moni-
toring of virus replication and spread in infected cells.
Expression of luciferase by the recombinant HeV-Luc
was assessed by infecting cells with various amounts of
virus for 24 hours. Luciferase activity in cells was then
measured by lysing the cells using BrightGlo reagent
(Promega) and reading on a Synergy H4 microplate
reader (Biotek Instruments Inc). As virus dose increased,
the level of luciferase increased proportionately (Figure 4).
Differences were observed when different cell lines were
used in this study, demonstrating the usefulness of this
virus to quantitatively assess the infection and/or replica-
tion efficiency of HeV in different cell lines. Luciferase ex-
pression can be used for high-throughput monitoring of
virus replication, hence they are a useful tool for screening
drug candidates. This virus is currently being used for a
genome-wide RNAi screen of human genes critical for
HeV replication.
In vivo characterisation
To determine whether the insertion of a reporter gene
into HeV attenuated the virus in vivo, ferrets were
exposed to 5,000 TCID50 of HeV-GFP virus by the
oronasal route. This dose was previously determined to
be lethal for ferrets using the parental wild-type isolate
Figure 5 Necrotising bronchoalveolitis with epithelial syncytia in lung of ferret infected with HeV-GFP virus. (a) H and E and (b)
immunohistochemical staining of HeV N protein showing presence of antigen in red. Arrow indicates syncytia.
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lenge and were euthanased on reaching pre-determined
humane endpoints on day 6 or day 7 post challenge [26].
Lesions in these animals included systemic vasculitis,
bronchoalveolitis, glomerular necrosis, and lymphoid ne-
crosis, associated with syncytial cell formation and HeV
antigen deposition in lesional tissues. Disease progres-
sion with the HeV-GFP virus was consistent with that
observed using wild-type virus, with ferrets becoming
febrile from 3 to 6 days post challenge and reaching pre-
determined humane endpoints on day 7 or 8 postFigure 6 Relative abundance of HeV-GFP RNA in different tissues of t
and analysed for HeV-GFP viral load by real-time PCR. Values are expressedchallenge (2 ferrets on each day). Gross post mortem
and microscopic pathology findings were also similar to
the previous report of HeV infection in ferrets. These in-
clude hemorrhagic lymph nodes and petechial hemor-
rhages throughout the lungs and renal cortices, with
necrotising rhinitis, systemic vasculitis, syncytial cell
formation, necrotising bronchoalveolitis (Figure 5),
lymphadenitis, and splenic and renal glomerular necrosis
accompanied by HeV antigen deposition in affected tis-
sues. Real-time PCR analysis of HeV RNA in clinical
samples and in tissues collected at euthanasia matchedhe ferret. Various tissues were collected at post mortem examination
relative to ribosomal 18S copies.
Figure 7 Expression of GFP in tissues sectioned from HeV-GFP
challenged ferrets. Ferrets were challenged with 5,000 TCID50 of
HeV-GFP and succumbed to disease on days 7 and 8. At necropsy,
kidney (a,b,c) and lung (d,e,f) samples were collected, fixed with
paraformaldehye, sectioned and imaged by confocal microscopy. To
assess sensitive of GFP expression (green; a and d) to traditional
staining techniques, HeV nucleocapsid protein (red; b and e) was co-
stained using rabbit anti- HeV N sera detected with anti-rabbit
conjugated Alexafluor 568. Composite images (c and f) show both
GFP and HeV N labelling. Scale bars: c =25 μm, f = 40 μm.
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Imaging of tissue sections from lung, kidney and
spleen of HeV-GFP infected ferrets by confocal micros-
copy showed significant numbers of GFP-containing
cells. To determine whether all infected cells were GFP-
positive, sections were co-stained for HeV nucleocapsid
(Figure 7). This showed that imaging of GFP expression
in tissues for HeV infection was as sensitive as immuno-
fluorescent labelling of tissue sections.
Conclusions
Here we report the first successful rescue of replication-
competent recombinant HeV, including both wild-type
HeV as well as recombinant viruses encoding either the
GFP or luciferase genes by genetic insertion between the
P and M genes. The rescue of the HeV-Luc virusresulted in a paramyxovirus with the largest functional
reported genome to date. Challenge of ferrets with HeV-
GFP demonstrated that the insertion of GFP into the
virus genome did not moderate its virulence, with GFP
expression being observed in tissues collected from fer-
rets at euthanasia. The HeV-Luc virus is currently being
utilized as a powerful tool for studying host genes im-
portant for the replication of HeV (unpublished data).
Methods
Cells and virus
293T cells (ATCC CRL-11268) were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) high glu-
cose (Invitrogen), supplemented with 10% fetal bovine
serum (FBS), 100 U/mL penicillin, 100 mg/mL strepto-
mycin, 4 mM L-glutamine. African green monkey (Vero
– ATCC CCL-81) cells were maintained in EMEM
supplemented with 10% FBS, 100 U/mL penicillin, and
100 mg/mL streptomycin. HeV (Hendra virus/horse/
1994/Hendra isolate, GenBank Accession AF017149)
was isolated in Vero cells from the lung of a horse
infected in the Brisbane outbreak in 1994 and was pas-
saged and triple plaque purified in Vero cells. All work
with live HeV was carried out within the BSL4 facilities
at the Australian Animal Health Laboratory, Geelong
Australia.
Generation of plasmids and rescue of recombinant HeVs
Vero cells were infected with HeV and when maximal
CPE was observed cell supernatants were collected and
virus concentrated by ultracentrifugation (280,000 g for
45 minutes). Pellet was then resuspended in buffer RLT
(Qiagen) and removed from the BSL4 laboratory. RNA
was extracted using a Qiagen RNEasy kit and reverse
transcribed to cDNA. Using a panel of PCR primers,
large (3–5 kb) fragments were generated by PCR and
cloned into pOLTV5 [27] between a T7 RNA promoter
and a hepatitis delta virus ribozyme. Full open reading
frames for HeV N, P and L genes, the essential compo-
nents needed for viral RNA transcription and replica-
tion, were cloned into pTM-I, a T7 driven mammalian
expression plasmid. In addition, the T7 RNA polymerase
gene was PCR amplified from BSR/T7 cells and cloned
into pCAGGS. All plasmid inserts were sequenced to
obtain at least 2-fold sequence coverage to ensure no
mutations relative to the reference sequences.
To generate recombinant viruses, 1 × 106 293T cells
were transfected with pTM-I HeV N (1.25 μg), pTM-I
HeV P (0.8 μg), pTM-I HeV L (0.4 μg), full-length HeV
genome plasmid (3.5 μg) and pCAGGS T7 (2 μg) using
7 μL Lipofectamine 2000 (Invitrogen). Media was
changed on cells at 6 hours post transfection and then
5 × 105 Vero cells were added to transfected 293T cells
after 2 days. Cells were observed for 7 days for the
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passaged to fresh Vero cells (75 cm2 flasks) to amplify
recombinant virus. When maximal CPE was obtained,
supernatants were clarified by low speed centrifugation
(1000 g), aliquoted, stored at −80°C and the 50% tissue
culture infective dose (TCID50)/mL calculated using the
Reed and Muench method [28].
Animal studies
Procedures involving live animals were approved by the
Commonwealth Scientific and Industrial Research Or-
ganisation, Australian Animal Health Laboratory and
Animal Ethics Committee. Four male ferrets, aged
12–18 months, were exposed oronasally to 5000 TCID50
of HeV-GFP. This challenge dose was selected as the
wild-type isolate has been shown to be lethal in ferrets
at this dose (unpublished observations). Ferrets were
monitored daily for indications of disease including
fever and alertness. Euthanasia was performed at
predetermined humane endpoints as previously de-
scribed [29]. Shedding samples, blood and urine were
collected on days 3 and 6 post-exposure as well as im-
mediately prior to euthanasia and various tissues col-
lected at post mortem examination.
Imaging of tissues
Samples of brain, lung, spleen and kidney tissues from
HeV-GFP infected ferrets were dissected into approxi-
mately 1 cm cubes and fixed for 48 hr in 4% paraformalde-
hyde in phosphate buffered saline (PBS). They were stored
at 4°C in PBS. Sections were cut at 70 μm on a Leica
VT1000 vibrating microtome (Leica Microsystems). Sec-
tions were blocked in PBS containing 0.5% bovine serum
albumin (PBS/BSA) overnight and then incubated in
rabbit anti-HeV N protein diluted 1:1000 in PBS/BSA. Fol-
lowing 3 × 10 min washes in PBS, the bound antibody was
detected with goat anti-rabbit IgG conjugated to Alexa
568 (Life Technologies) diluted 1:200 in PBS/BSA,
followed by 3 × 10 min washes in PBS. Nuclei were la-
belled by incubation of sections in a 1:1000 dilution of
DAPI (Sigma, Sydney) for 30 min and following 2 × H2O
washes, the sections were mounted in Vectashield (Vector
laboratories). Coverslips were sealed with nail varnish and
the sections imaged with a Leica SP5 confocal microscope.
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